The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
More than 40 types of Amyloid proteins are discovered till date
Final decision from the European Commission is anticipated within the coming months
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
